-
Teva comes up as front-runner to buy Cephalon
JERUSALEM — Cephalon has another suitor in the form of the world’s largest generic drug company.
Teva Pharmaceutical Industries said Monday that it would buy Frazer, Pa.-based Cephalon for $6.8 billion, undercutting efforts by Valeant Pharmaceuticals International, which had offered $5.7 billion in March.
The boards of both companies have agreed to the acquisition, equal to $81.50 per share. Cephalon previously had turned down Valeant’s offer, prompting the Mississauga, Ontario-based company to take its case directly to Cephalon’s shareholders.
-
AmerisourceBergen posts 2.4% increase in revenue
VALLEY FORGE, Pa. — AmerisourceBergen on Thursday posted revenue of $19.8 billion, up 2.4%, for its second quarter ended March 31.
"In the March quarter, we delivered outstanding performance on top of very strong performance last year," stated David Yost, AmerisourceBergen CEO.